Wolverine Trading, LLC Abb Vie Inc. Call Options Transaction History

Wolverine Trading, LLC

$94.2 Billion
Q2 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $9.72 Million - $11.4 Million	62,800 Added 12.04%	584,400 $100 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $431,514 - $491,670	2,700 Added 0.52%	521,600 $95 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $11.3 Million - $12.7 Million	82,100 Added 18.8%	518,900 $80.4 Million
Q3 2023 Nov 15, 2023	SELL	$133.59 - $154.65 $26.7 Million - $30.9 Million	-199,900 Reduced 31.4%	436,800 $65.1 Million
Q2 2023 Aug 23, 2023	BUY	$132.51 - $164.9 $20.9 Million - $26 Million	157,400 Added 32.84%	636,700 $85.8 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $15.2 Million - $17.5 Million	105,000 Added 28.05%	479,300 $75.7 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $21.6 Million - $26 Million	156,500 Added 71.85%	374,300 $60.5 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $7.1 Million - $8.14 Million	-52,900 Reduced 19.54%	217,800 $31.1 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $9.25 Million - $11.8 Million	-67,200 Reduced 19.89%	270,700 $41.7 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $30.6 Million - $38 Million	-232,200 Reduced 40.73%	337,900 $55.3 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $4.02 Million - $5.08 Million	37,400 Added 7.02%	570,100 $77.5 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $10.5 Million - $11.9 Million	98,300 Added 22.63%	532,700 $58 Million
Q2 2021 Aug 06, 2021	BUY	$105.21 - $117.21 $10.4 Million - $11.6 Million	99,300 Added 29.63%	434,400 $48.8 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $5.98 Million - $6.59 Million	58,500 Added 21.15%	335,100 $35.8 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $3.73 Million - $5.03 Million	46,300 Added 20.1%	276,600 $29.1 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $7.19 Million - $8.44 Million	-83,700 Reduced 26.66%	230,300 $20 Million
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $5.86 Million - $7.84 Million	-79,900 Reduced 20.28%	314,000 $30.3 Million
Q1 2020 May 11, 2020	BUY	$64.5 - $97.79 $5.42 Million - $8.22 Million	84,100 Added 27.15%	393,900 $29.6 Million
Q4 2019 Feb 12, 2020	SELL	$72.13 - $90.25 $2.45 Million - $3.06 Million	-33,900 Reduced 9.86%	309,800 $27.4 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $2.08 Million - $2.51 Million	33,100 Added 10.66%	343,700 $25.7 Million
Q2 2019 Aug 20, 2019	SELL	$65.7 - $83.98 $2.4 Million - $3.07 Million	-36,600 Reduced 10.54%	310,600 $22.6 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $1.74 Million - $2.05 Million	22,600 Added 6.96%	347,200 $28 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $5.68 Million - $7.01 Million	73,000 Added 29.01%	324,600 $29.6 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $4.18 Million - $4.65 Million	-47,000 Reduced 15.74%	251,600 $23.8 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $36,804 - $49,284	-400 Reduced 0.13%	298,600 $28.3 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $26.8 Million - $29.4 Million	299,000	299,000 $28.9 Million

Others Institutions Holding ABBV

# of Institutions

3,771

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.83M

Vanguard Group Inc Valley Forge, PA

171M
Shares

$34.7 Billion
0.57% of portfolio
Black Rock Inc. New York, NY

136M
Shares

$27.8 Billion
0.54% of portfolio
State Street Corp Boston, MA

77.8M
Shares

$15.8 Billion
0.59% of portfolio
Jpmorgan Chase & CO New York, NY

53.6M
Shares

$10.9 Billion
0.81% of portfolio
Capital International Investors Los Angeles, CA

38.6M
Shares

$7.86 Billion
1.4% of portfolio

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $360B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account